Clinical characteristics and outcomes of 17 cases of inflammatory myofibroblastic tumor at a University Hospital in China

Song,Wei; Zhu,Yan

doi:10.3892/ol.2020.12312

Clinical characteristics and outcomes of 17 cases of inflammatory myofibroblastic tumor at a University Hospital in China

Authors:
- Wei Song
- Yan Zhu
View Affiliations

Affiliations: Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: November 18, 2020 https://doi.org/10.3892/ol.2020.12312
Article Number: 51
Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to explore the clinical and pathological characteristics, diagnosis, and treatment of inflammatory myofibroblastic tumor (IMT). A total of 17 patients with IMT diagnosed between July 2010 and February 2020 were included in the present study, and the clinical characteristics, pathological features, treatment and prognosis were analyzed retrospectively. The cohort consisted of 17 participants, including 12 men and 5 women, with a mean age of 34.76 years. The most common locations of tumors were the bronchi and the lungs (9 cases, including 1 case involving the mediastinum), followed by the colon and bladder (2 cases each), and the omentum majus, mesocolon, stomach and peritoneal cavity (1 case each). Immunohistochemical staining demonstrated that the tumor cells exhibited positive staining for anaplastic lymphoma kinase p80 (13/17), smooth muscle actin (12/17), cytokeratin pan (6/17), vimentin (5/17) and desmin (4/17). The follow-up time was 18-114 months. A patient with epithelial inflammatory myofibroblast sarcoma (EIMS) succumbed to the disease, 1 case was lost to follow-up, 2 cases relapsed and the other 13 cases were considered cured. IMTs may be malignant or low-grade. EIMS is a rare and invasive variant of IMT. The clinical and imaging manifestations are often unique and vary among individuals. Once confirmed by pathology, radical surgery should be the first choice of treatment.

View Figures

View References

1	Oztuna F, Pehlivanlar M, Abul Y, Tekinbas C, Ozoran Y and Ozlu T: Adult inflammatory myofibroblastic tumor of the trachea: Case report and literature review. Respir Care. 58:e72–e76. 2013. View Article : Google Scholar : PubMed/NCBI
2	Yamamoto H: WHO Classification of Tumours Editorial Board. Fibroblastic/myofibroblastic Tumors. WHO Classification of Tumors of Soft Tissue and Bone. 5th edition. International Agency for Research on Cancer; Lyon, France: pp. 109–112. 2020
3	Gleason BC and Hornick JL: Inflammatory myofibroblastic tumours: Where are we now? J Clin Pathol. 61:428–437. 2008. View Article : Google Scholar : PubMed/NCBI
4	Ding R, Li X, Zhu XM, Song QX, Fan QH, Zhang ZH and Gong QX: Inflammatory myofibroblastic tumor arising from soft tissues of extremities harboring a novel CLIP2-ALK fusion. Pathol Int. 70:798–803. 2020. View Article : Google Scholar : PubMed/NCBI
5	Liu H, Lin J, Yang P, Shen H and Yang H: Whether inflammatory myofibroblastic tumor of the thigh relapses after surgical excision? Int J Clin Exp Med. 8:11584–11588. 2015.PubMed/NCBI
6	Mariño-Enríquez A, Wang WL, Roy A, Lopez-Terrada D, Lazar AJ, Fletcher CD, Coffin CM and Hornick JL: Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol. 35:135–144. 2011. View Article : Google Scholar : PubMed/NCBI
7	Du X, Gao Y, Zhao H, Li B, Xue W and Wang D: Clinicopathological analysis of epithelioid inflammatory myofibroblastic sarcoma. Oncol Lett. 15:9317–9326. 2018.PubMed/NCBI
8	Sarmiento DE, Clevenger JA, Masters GA, Bauer TL and Nam BT: Epithelioid inflammatory myofibroblastic sarcoma: A case report. J Thorac Dis. 7:E513–E516. 2015.PubMed/NCBI
9	Lee JC, Li CF, Huang HY, Zhu MJ, Mariño-Enríquez A, Lee CT, Ou WB, Hornick JL and Fletcher JA: ALK oncoproteins in atypical inflammatory myofibroblastic tumours: Novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma. J Pathol. 241:316–323. 2017. View Article : Google Scholar : PubMed/NCBI
10	Liu Q, Kan Y, Zhao Y, He H and Kong L: Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: A case report and review of literature. Int J Clin Exp Pathol. 8:15328–15332. 2015.PubMed/NCBI
11	Shukla PS and Mittal K: Inflammatory myofibroblastic tumor in female genital tract. Arch Pathol Lab Med. 143:122–129. 2019. View Article : Google Scholar : PubMed/NCBI
12	Chougule A, Bal A, Das A, Agarwal R, Singh N and Rao KL: A comparative study of inflammatory myofibroblastic tumors and tumefactive IgG4-related inflammatory lesions: The relevance of IgG4 plasma cells. Appl Immunohistochem Mol Morphol. 24:721–728. 2016. View Article : Google Scholar : PubMed/NCBI
13	Zhu L, Li J, Liu C, Ding W, Lin F, Guo C and Liu L: Pulmonary inflammatory myofibroblastic tumor versus IgG4-related inflammatory pseudotumor: Differential diagnosis based on a case series. J Thorac Dis. 9:598–609. 2017. View Article : Google Scholar : PubMed/NCBI
14	Taylor MS, Chougule A, MacLeay AR, Kurzawa P, Chebib I, Le L and Deshpande V: Morphologic overlap between inflammatory myofibroblastic tumor and IgG4-related disease: Lessons from next-generation sequencing. Am J Surg Pathol. 43:314–324. 2019. View Article : Google Scholar : PubMed/NCBI
15	Pecoraro Y, Diso D, Anile M, Russo E, Patella M and Venuta F: Primary inflammatory myofibroblastic tumor of the trachea. Respirol Case Rep. 2:147–149. 2014.PubMed/NCBI
16	Wang S, Chen L, Cao Z, Mao X, Zhang L and Wang B: Inflammatory myofibroblastic tumor of the lumbar spinal canal: A Case Report With Literature Review. Medicine (Baltimore). 96:e64882017. View Article : Google Scholar : PubMed/NCBI
17	Sukov WR, Cheville JC, Carlson AW, Shearer BM, Piatigorsky EJ, Grogg KL, Sebo TJ, Sinnwell JP and Ketterling RP: Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder. Mod Pathol. 20:592–603. 2007. View Article : Google Scholar : PubMed/NCBI
18	Cook JR, Dehner LP, Collins MH, Ma Z, Morris SW, Coffin CM and Hill DA: Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: A comparative immunohistochemical study. Am J Surg Pathol. 25:1364–1371. 2001. View Article : Google Scholar : PubMed/NCBI
19	Mossé YP, Voss SD, Lim MS, Rolland D, Minard CG, Fox E, Adamson P, Wilner K, Blaney SM and Weigel BJ: Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: A children's oncology group study. J Clin Oncol. 35:3215–3221. 2017. View Article : Google Scholar : PubMed/NCBI
20	Watanabe H, Uruma T, Tazaki G, Tajiri T, Kikuchi R, Itoh M, Aoshiba K and Nakamura H: Remission of ALK-negative primary pulmonary inflammatory myofibroblastic tumor on treatment with clarithromycin: A case report and review of the literature. Oncol Lett. 11:1757–1761. 2016. View Article : Google Scholar : PubMed/NCBI